Stephen Donald Wilton

This inventor holds 48 USPTO granted patents and 34 published patent applications and 9 EPO patents, primarily in Antisense Oligonucleotides. Top assignees: The University of Western Australia, Murdoch University, Université De Mons. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Donald Wilton. Retrieved from https://idiyas.com/inventor/stephen-donald-wilton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 48 (Patent Applications = 34)

% Patents Active = 97.9

EPO Patents = 9 (Patent Applications = 24)

Average Co-Inventor Count = 3.3

ph-index = 28

Forward Citations = 2,202(Granted Patents)

Location History:

Perth, AU (2021)
Murdoch, AU (2022 - 2023)
Applecross, AU (2010 - 2024)

Company Filing History:

37 out of 109

The University of Western Australia

Beijing University of Technology

patents

5. 2 out of 127

Sarepta Therapeutics, Inc.

patents

6. 2 out of 916

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

7. 1 out of 179

Nationwide Children's Hospital

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Antisense Oligonucleotides

Muscular Dystrophy

CFTR Function

Exon Skipping

RNA Modulation

Splicing Modulation

NEAT1 Associated Disease

Facioscapulohumeral Dystrophy

Multiple Sclerosis

Pathology Treatment

Receptor Modulation

Advanced Glycation End-Products

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12709749 - ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES (2026-08-18),

2. 12565656 - MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA (2026-03-03),

3. 11898143 - Agents useful in treating facioscapulohumeral muscular dystrophy (2024-02-13),

4. 11674143 - Modulators and modulation of the receptor for advanced glycation end-products RNA (2023-06-13),

5. 11459563 - Treatment for NEAT1 associated disease (2022-10-04),

6. 11447776 - Antisense molecules and methods for treating pathologies (2022-09-20),

7. 11441148 - Modulators and modulation of the receptor for advanced glycation end-products RNA (2022-09-13),

8. RE48960 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2022-03-07),

9. 11236338 - Antisense-induced exon2 inclusion in acid alpha-glucosidase (2022-02-01),

10. 11053494 - Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene (2021-07-06),

11. 10995337 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-05-04),

12. 10968450 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-04-06),

13. 10907157 - Agents useful in treating facioscapulohumeral muscular dystrophy (2021-02-02),

14. 10781451 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2020-09-22),

15. 10781450 - Antisense molecules and methods for treating pathologies (2020-09-22),

Title: The Innovative Contributions of Stephen Donald Wilton in Muscular Dystrophy Research

Introduction

Stephen Donald Wilton, based in Applecross, Australia, is a prominent inventor recognized for his significant contributions to the field of medical research and biotechnology. With an impressive portfolio of 46 patents, Wilton has focused primarily on innovations aimed at addressing muscular dystrophies.

Latest Patents

Among his latest patents, Wilton has developed agents useful in treating facioscapulohumeral muscular dystrophy. These include antisense agents and RNA interference agents that target double homeobox 4 and double homeobox 4c. The methodologies provide new avenues for treating diseases by modulating gene expression. Another significant patent involves modulators for the receptor for advanced glycation end-products (RAGE). This patent describes an isolated or purified antisense oligonucleotide (AON) that modifies pre-mRNA splicing in RAGE, offering further insights into therapeutic applications for this receptor.

Career Highlights

Wilton's career has been marked by his association with esteemed institutions such as The University of Western Australia and Murdoch University. His work in these environments has facilitated groundbreaking research in genetic therapies and muscular disorders.

Collaborations

Throughout his extensive career, Stephen Wilton has collaborated with notable coworkers, including Sue Fletcher and Graham McClorey. These partnerships have further enriched his research endeavors, contributing to developments that are poised to make a real impact in the treatment of muscular dystrophies.

Conclusion

Stephen Donald Wilton continues to be a pivotal figure in the realm of biotechnology and medical research. His numerous patents and collaborative efforts underscore his commitment to advancing our understanding and treatment of muscular dystrophy, making him an influential inventor in this critical field. His work exemplifies the innovation needed to drive progress in healthcare solutions.

Profile summary based on public USPTO records.